Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis C Virus
Development Discontinued for ANA975, an Early Stage Compound for Treatment of Hepatitis C Virus Infection
August 14th, 2007
Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS) announced that it and Novartis have decided to discontinue the development of ANA975, a phase 1b compound for the treatment of hepatitis C virus (HCV) infection. The parties have determined that the results received to date from the ongoing 13 week toxicology study together with the results observed in the previous 13 week toxicology study do not support further clinical evaluation of chronic daily dosing of ANA975 in hepatitis C patients. "Although we are disappointed to discontinue development of ANA975, our animal toxicology results have convinced us that chronic daily dosing of this compound is inappropriate for further...
Source: Virus Weekly (2007-08-14)
|
